Investing.com – Canaccord raised its worth goal on shares (NASDAQ:TSHA) to $17 from $14 whereas sustaining a Purchase score on Monday. The improve aligns with the broader analyst consensus of Robust Purchase, although the inventory at present trades at $4.37, effectively beneath the brand new goal. In line with InvestingPro information, TSHA has delivered a outstanding 258% return over the previous 12 months, although the platform’s Truthful Worth evaluation suggests the inventory could also be overvalued at present ranges.
The corporate reiterated that dosing completion in each its REVEAL and ASPIRE trials is anticipated within the second quarter of 2026. The FDA just lately cleared initiation of ASPIRE, the place three sufferers aged 2 to underneath 4 years previous will obtain a 1E15 dose scaled all the way down to account for decrease mind quantity within the youthful inhabitants.
Up to date Half An information is anticipated within the second quarter of 2026, when all 12 sufferers could have a minimal of 12 months of follow-up. Among the many 10 sufferers for whom information has been shared, together with 5 with lower than 12 months of follow-up, 100% have demonstrated a minimum of one milestone achieve.
The corporate famous that interim six-month pivotal information ought to be out there by year-end 2026, together with completion of PPQ tons. Administration doesn’t anticipate to share the information publicly till there’s FDA alignment on subsequent steps.
Canaccord acknowledged that continued proof of milestone positive aspects and a clear security profile will help the pivotal trial. For deeper insights into TSHA’s monetary well being and complete evaluation, buyers can entry the corporate’s Professional Analysis Report, out there completely on InvestingPro alongside 1,400+ different US equities.
In different latest information, Taysha Gene Therapies reported a internet lack of $109.0 million for the complete 12 months ending December 31, 2025, which interprets to a lack of $0.34 per share. This represents a rise from the earlier 12 months’s internet lack of $89.3 million, or $0.36 per share. Regardless of the widened loss, the corporate continues to advance its gene remedy trials. Jefferies raised its worth goal for Taysha Gene Therapies to $13.00, up from $11.00, whereas sustaining a Purchase score, in mild of trial progress. The corporate plans to current up to date REVEAL Half An information within the second quarter and goals to finish enrollment for its pivotal trial. Raymond James reiterated a Robust Purchase score with a $13.00 worth goal, citing confidence in administration’s technique to file on 6-month REVEAL Half B information. Moreover, Cantor Fitzgerald reiterated an Obese score and a $19.00 worth goal, noting promising Part 1/2 information. These latest developments mirror ongoing curiosity and evaluation from varied funding companies.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
